Aerie Pharmaceuticals Inc (NASDAQ:AERI) has been assigned an average recommendation of “Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $71.77.
A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Mizuho reiterated a “buy” rating and issued a $87.00 price objective on shares of Aerie Pharmaceuticals in a report on Monday, January 29th. Seaport Global Securities assumed coverage on shares of Aerie Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $78.00 price objective on the stock. Canaccord Genuity lifted their price objective on shares of Aerie Pharmaceuticals from $73.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd.
Aerie Pharmaceuticals (AERI) traded down $1.60 during midday trading on Friday, hitting $52.55. 304,200 shares of the stock were exchanged, compared to its average volume of 377,847. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 12 month low of $38.14 and a 12 month high of $66.60. The firm has a market capitalization of $2,030.00, a P/E ratio of -16.54 and a beta of 0.87.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.